Radium-223 for the treatment of castration-resistant prostate cancer
Joelle El-Amm, Jeanny B Aragon-Ching Division of Hematology and Oncology, George Washington University Medical Center, Washington, DC, USA Abstract: The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-05-01
|
| Series: | OncoTargets and Therapy |
| Online Access: | http://www.dovepress.com/radium-223-for-the-treatment-of-castration-resistant-prostate-cancer-peer-reviewed-article-OTT |